Table 3.
Severity of neutropenia as determined by VCOG‐CTCAE for dogs that received either commercially available lomustine or a compounded formulation of lomustine
| Severity of neutropenia | Neutrophil Count (cell/μL) | FDA‐Approved Lomustine (n = 21) | Compounded Lomustine (n = 16) |
|---|---|---|---|
| None | WNLa | 0 | 12 (75%) |
| Grade 1 (mild) | 1,500 – LLNb | 2 (9.5%) | 1 (6.3%) |
| Grade 2 (moderate) | 1,000–1,499 | 4 (19%) | 1 (6.3%) |
| Grade 3 (severe) | 500–999 | 5 (24%) | 2 (12.5%) |
| Grade 4 (life‐threatening) | <500 | 9 (43%) | 0 |
| Grade 5 (death) | – | 1 (4.8%) | 0 |
a
WNL, within normal limits.
b
LLN, lower limit of normal.